Floatz Rating
CCC50/100
Confidence
Indicative
Sponsor
Shenzhen Geno-Immune Medical Institute
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04637503CT.gov 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma | — | Recruiting | — | — | — |
NCT04864821CT.gov Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Neuroblastoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Targeting Cd276 Car T Cells (this asset) | Shenzhen Geno-Immune Medical Institute | P1/2 | CCC · 50 |
| Nivestim | M.D. Anderson Cancer Center | P4 | BB |
| Etoposide | M.D. Anderson Cancer Center | P2/3 | BB |
| Cyclophosphamide | Robbie Majzner | P2 | BB |
| Carboplatin | St. Jude Children's Research Hospital | P2/3 | BB |
| Gm-Csf | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | P4 | BB |
| Melphalan | M.D. Anderson Cancer Center | P2/3 | BB |
| Nogitecan | Novartis Pharmaceuticals | P2 | BB |
| Adriamycin | Hoffmann-La Roche | P2 | BB |
+42 more in the Neuroblastoma cohort
Other indications for Targeting Cd276 Car T Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Exocrine Pancreatic Carcinoma | — | P1/2 | CCC · 48 |
| Osteosarcoma | — | Early P1 | C · 38 |
| Gastric Cancer | — | Early P1 | C · 34 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Targeting Cd276 Car T Cells in Neuroblastoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/targeting-cd276-car-t-cells-neuroblastoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →